AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant + Abemaciclib
Description: Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
Study NCT01333488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
Study NCT04522024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epicardial focal cryoablation
Description: Epicardial focal cryoablation on the left atrium around right upper pulmonary vein area
Study NCT04522024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mei Mini Maze procedure
Description: Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side
Study NCT03128879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03128879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03128879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given BID
Study NCT02915029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and lifestyle coaching
Description: Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month.
Study NCT00754182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate (Dermabond)
Description: Synthetic glue for surgical use (skin closure)
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant + Letrozole
Description: Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788 + Cemiplimab
Description: ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV1 + Cemiplimab
Description: VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
Study NCT00754182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular reabsorbable suture (Caprosyn)
Description: Every stitch is positioned in the subcuticular tissue by a continuous technique
Study NCT02993679 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: reconstruction of the ACL and anterolateral ligament
Description: reconstruction of the ACL and anterolateral ligament
Study NCT03376178 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and ropivacaine injection through catheters
Description: injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan + Durvalumab
Description: Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
Study NCT03376178 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: lidocaine and ropivacaine injection through catheters
Description: injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Description: Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
Study NCT04107571 — intervention group
Intervention type: PROCEDURE
Intervention: A type of operation for coranary heart disease patients.
Description: A type of operation for coranary heart disease patients.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-endoxifen
Description: Z-endoxifen: 10 mg QD, p.o., for 24 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: ARV-471: 200 mg QD, p.o, for 24 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471 + Letrozole
Description: ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471 + Abemaciclib
Description: ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxifen + Abemaciclib
Description: Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig + TDXd
Description: Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dan222 + Niraparib
Description: DAN222: 8mg/m2 IV QW for 12 weeks Niraparib: 200mg QD p.p., 12 weeks
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab + Cemiplimab + Paclitaxel
Description: Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks
Study NCT02306967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of oral cancer
Description: Oral cancer will be resected.
Study NCT02306967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resection of oral cancer
Description: Oral cancer will be resected.
Study NCT02306967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of oral cancer
Description: Oral cancer will be resected
Study NCT02306967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resection of oral cancer
Description: Oral cancer will be resected
Study NCT02872922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity therapeutic ultrasound
Description: The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
Study NCT04409028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronal restoration
Description: A restorative material like composite resin is condensed into the cavity of teeth.
Study NCT02748577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
Study NCT02748577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
Study NCT02748577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Testing (QST) Pain Measurements
Description: Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
Study NCT02748577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing (QST) Pain Measurements
Description: Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
Study NCT02009033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
Study NCT02009033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch
Study NCT04088682 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality improvement strategies and tools
Description: Quality improvement strategies and tools
Study NCT02645916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danggui-Sayuk-Ga-Osuyu-Saenggang-tang
Description: Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study NCT02645916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: corn starch
Description: Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study NCT01996969 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Regorafenib
Description: Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
Study NCT01546116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADEFOVIR, LAMIVUDINE
Description: Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
Study NCT00414661 — intervention group
Intervention type: DRUG
Intervention: CP-690,550
Description: Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
Study NCT06650345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised aerobic exercise
Description: In this training program, the participants exercised for 45-60 minutes through intervals on a treadmill, bike, or stair climber, three times a week for 12 weeks.
Study NCT01197469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 10mg once daily for 3 months
Study NCT01197469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03710278 — intervention group
Intervention type: DEVICE
Intervention: LPat Device
Description: Performing Lumbar Puncture utilizing LPat device
Study NCT03031288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A
Description: standard bottle
Study NCT03031288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B
Description: vented base bottle
Study NCT04126928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.
Study NCT03235024 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B244
Description: B244 suspension
Study NCT03235024 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle suspension
Study NCT00357370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, once daily, up to 12 weeks
Study NCT00357370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, up to 12 weeks
Study NCT03775668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 µCi of 14C-AAI101 + 500 mg AAI101
Description: Single dose open label
Study NCT06469255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Treatment
Description: 4 weeks low calorie diet treatment
Study NCT02432716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
Study NCT02432716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
Study NCT02100891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HCT
Description: Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
Study NCT02100891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor NK Cell Infusion
Description: Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
Study NCT01790464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine
Description: 2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
Study NCT01790464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04469361 — intervention group
Intervention type: OTHER
Intervention: Navicular drop measurement
Description: The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.
Study NCT04469361 — intervention group
Intervention type: OTHER
Intervention: Measurement of venous return parameters in supine
Description: Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position
Study NCT04469361 — intervention group
Intervention type: OTHER
Intervention: Measurement of venous return parameters in standing
Description: In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.
Study NCT04469361 — intervention group
Intervention type: OTHER
Intervention: measurement of midfoot pressure distrubition
Description: In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
Study NCT01038271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Palliative Care Group
Description: Participant is referred to the Palliative Care Team at any time.
Study NCT01038271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Palliative Care Intervention
Description: Participant meets with the Palliative Care Team within 3 weeks of being randomized
Study NCT01978431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocaine hydrochloride
Study NCT01978431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylphenidate
Study NCT01978431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Study NCT04169295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gynecologists' feedback on ART-Birth rates
Description: At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.
Study NCT04169295 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
Study NCT02357576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid 20% I.V. Fat Emulsion
Study NCT02357576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20% I.V. Fat Emulsion
Study NCT06651125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: Patients in the Adapted Physical Activity arm realized a 12-weeks supervised exercise program. The supervised PA intervention consisted of two sessions per week. Each session lasted one hour and was divided into 30 minutes of aerobic exercise using an ergometer (treadmill and/or bicycle), followed by 30 minutes of resistance exercises involving major muscle groups, with or without small equipment such as dumbbells, resistance bands, and balls. The exercise regimen was carried out at an intensity ranging from 50% to 70% of the heart rate reserve, with a rate of perceived exertion (RPE) set at 4 on a Borg scale of 0 to 10. A total of 24 sessions were planned. There was also the option to incorporate a 45-minute session of moderate-intensity water aerobics into the weekly routine.
Study NCT01987323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of liposomal latanoprost
Study NCT03101475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
Study NCT03101475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
Study NCT03101475 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterotactic body radiation therapy (SBRT)
Description: delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
Study NCT03586739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computerized tomography scan (CT-scan)
Description: a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up.
Study NCT03586739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: digital angiography
Description: In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
Study NCT03586739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital angiography
Description: In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
Study NCT03586739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short Form-36 (SF-36) questionnaire
Description: The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
Study NCT03586739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Form-36 (SF-36) questionnaire
Description: The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
Study NCT03101475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
Study NCT01567176 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
Study NCT03829735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: Collection of capillary blood for HbsAg testing. Collection of 12 mL of blood for HbsAg positive women and 1 mL for HbsAg positive children.
Study NCT03081416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intranasal ketamine administration
Study NCT03081416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Study NCT03081416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Standard therapy
Study NCT03081416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: standard therapy
Study NCT03081416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Standard therapy